Although this is counterintuitive because the use of potent synthetic PPARγ ligands such as insulin sensitizers, like pioglitazone, cause modest increases in plasma SHBG levels in individuals with the metabolic syndrome (Sridhar et al. 2013), the effects of these potent drugs may be multifactorial. The gene discussed is SHBG; the disease is metabolic syndrome.